西格列汀联合二甲双胍对2型糖尿病患者胰岛素抵抗、血脂和血压的影响被引量：48

Effects of sitagliptin and metformin on insulin resistance,blood lipid and blood pressure in patients with type 2 diabetes

在线阅读下载PDF

导出

摘要目的观察西格列汀联合二甲双胍对2型糖尿病患者胰岛素抵抗、血脂和血压等心血管危险因素的影响。方法选择病史在5年以内的2型糖尿病患者60例,随机分为3组:西格列汀(A)组、二甲双胍(B)组、二甲双胍+西格列汀(C)组。服药前和服药后12周分别检测患者体重、身高、空腹血糖(FBG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、胆固醇(TCH)、低密度脂蛋白(LDL-C)、收缩压(SBP)、舒张压(DBP),并计算其体重指数(BMI)、胰岛素抵抗指数(HOMA-IR)。结果①各组用药前比较,FBG、HbA1c、BMI、TG、TCH、LDL-C、SBP、DBP均下降(P<0.05)。C组HOMA-IR用药前后比较差异有统计学意义(P<0.05)。②用药后,A组与C组及B组与C组FBG、HbA1c、TG、TCH、LDL-C、SBP、DBP比较差异均有统计学意义(P<0.05);A组与B组及A组与C组BMI比较差异有统计学意义(P<0.05),B组与C组BMI比较差异无统计学意义;用药后3组HOMA-IR组间比较差异无统计学意义。结论西格列汀、二甲双胍对降低血糖、调节血脂、控制血压、减轻胰岛素抵抗均有作用。二者联合用药后其降糖、调脂、降压、减轻胰岛素抵抗作用较单独用药效果更好。 Objective To assess the effects of sitagliptin and metformin on insulin resistance, blood lipid and blood pressure in patients with type 2 diabetes mellitus（T2DM）. Methods 60 patients with T2DM, a history of less than 5 years, were randomly divided into three groups： the sitagliptin group （A）, the metformin group （B）, the metformin ＋ sitagliptin group （C）. Before taking into the measurement, patients should be tested in weight, height, fasting blood glucose, fasting insulin, HbAlc, TG, TCH, LDL-C, SBP, DBP, and calculating body mass index（ BMI）, the insulin resistance index （HOMA-IR）. After 12 weeks of medication, all the data were retested. Results （1） After treatment compared with before, FBG, HbAlc, BMI, TG, TCH, LDL-C, SBP, DBP decreased （P 〈0. 05）. There was statistically significant difference between pre-therapy and post-treatment in group C. （2） Group A compared with group C, group B compared with group C, the levels of FBG, HbAlc, TG, TCH, LDL-C, SBP, DBP were statistically significant （P 〈 0.05）. Group A and group B were not statistically significant. There was no statistical significance between the three groups in BMI and HOMA-IR. Conclusion Sitagliptin and metformin have the effects in lowing glucose, improving lipids, reducing insulin resistance, and combination therapy is better than single drug effect.

作者吕珊珊潘天荣钟兴杜益君王秀艳

机构地区安徽医科大学第二附属医院内分泌科

出处《安徽医科大学学报》 CAS 北大核心 2014年第1期107-109,共3页 Acta Universitatis Medicinalis Anhui

基金安徽医科大学校科研基金(编号:2011xkj055)

关键词 2型糖尿病西格列汀二甲双胍血脂血压 type 2 diabetes mellitus sitagliptin metformin blood lipid blood pressure

分类号 R977.15 [医药卫生—药品] R544 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献9

1Sivertsen J, Rosenmeier J, Holst J J, et al. The effect of gluca- gon-like peptidel on cardio-vascular risk [ J ]. Nat Rev Cardiol, 2012, 9(4) :209 -22.
2Mu J, Woods J, Zhou Y P, et al. Chronic inhibition of dipeptidy peptidase-4 with a sitagliptin analog preserves pancreatic 13-cellmass and function in a rodent model of type 2 diabetes[ J]. Diabe- tes ,2006,55 ( 6 ) : 1695 - 1704.
3Flock C, Baggio L L, Longuet C, et al. Incretin receptors for glu- cagon-like peptide 1 and glucose-dependent insulin otropic poly- peptide are essential for the sustained metabolication of vildagliptin in mice[J]. J Diabetes, 2007, 56(4): 3006-13.
4Monami M, Lacomellil, Marchionni N, et al. Dipeptydil peptidase - 4 inhibitors in type 2 diabetes: ameta-analysis of randomized clini- cal trials[J]. Nun" Metab Cardiovase Dis,2010,20(4) : 224 -35.
5Jendle J, Nauck M A, Matthews D R, et al. Weight loss with lira- glutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue[J]. Diabetes Obes Metab ,2009,11 ( 12 ) : 1163 - 72.
6Charbonnel B, Karasik A, Liu J , et al. Efficacy and safety of the dipeptidy peptidase-4 inhibitor sitagliptin added to ongoing met- formin therapy in patients with type 2 diabetes inadequately con- trolled with metformin alone[ J]. Diabetes Care,2006, 29 (12) : 2638 - 43.
7沈晓霞,李光伟.DPP-4抑制剂的多中心临床试验研究进展[J].药品评价,2009,6(1):24-25. 被引量：2
8Buse J B, Polonsky K S, Burant C F,et al. Type 2 diabetes melli- tus in 2010: individualizing treatment targets in diabetes care[ J]. Nat Rev Endocrinol, 2011,7(2) :67 -8.
9Tremblay A J, Lamarche B, Lemelin N, et al. Effect of sitagliptin therapy on postprandial lipoprotein level in patient with type 2 dia- betes[J]. Diabetes Obes Metab,2011,13(4) : 366 -73.